Is Trastuzumab Every Three Weeks Ready for Prime Time?
- 1 November 2003
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (21) , 3900-3901
- https://doi.org/10.1200/jco.2003.07.984
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With PaclitaxelJournal of Clinical Oncology, 2003
- Cardiac Dysfunction in the Trastuzumab Clinical Trials ExperienceJournal of Clinical Oncology, 2002
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.Journal of Clinical Oncology, 1998
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.Journal of Clinical Oncology, 1996